Hyperspectral Imaging Shows Promise in Solving Diagnostic Dilemmas in Pathology

Raman molecular imaging (RMI), a form of hyperspectral imaging, shows promise in identifying cancers that are typically difficult to diagnose. Its history, successes and current advancements will be discussed at the International Conference on Raman Spectroscopy (ICORS), Aug. 13 from 8:30 – 10:00 a.m. at the Boston Park Plaza Hotel in Boston.

Presented by Shona Stewart, Ph.D., senior scientist at ChemImage, “Advancing Raman Molecular Imaging for Disease Diagnosis” will discuss application of RMI in histopatholgy settings.

“As RMI is still an evolving technology, we’re looking forward to sharing this important work with an international group of our peers and gaining some valuable feedback,” said Dr. John Maier, Vice President of Biomedical Research at ChemImage. 

RMI combines image information familiar to clinicians with spectral data in each pixel to imprint a digital molecular stain, unique to each sample, without the use of reagents. Images are acquired from tissue samples illuminated by a laser in a microscope and then analyzed by chemometric-based classification algorithms.

So far, RMI has shown great success in differentiating disease states in tissue, especially from the kidney and prostate. ChemImage continues to conduct and present RMI research on how it can:

  • Discriminate between two challenging kidney disease diagnoses: oncocytoma, a benign condition and chromophobe renal cell carcinoma, a malignant one.
  • Predict progression in prostate cancer, where slow-growing prostate cancer is difficult to differentiate from more aggressive forms.

For more information on RMI’s role in pathology, click here.

About ChemImage Corporation

ChemImage Corporation is a Pittsburgh based company committed to making the world healthier and safer through dramatic advancements in chemical imaging technology. The company combines proprietary, state-of-the-art imaging sensors, algorithms and analytical software to solve the world's most challenging health and safety issues.

ChemImage seeks to provide an Awareness of Things™ (AoT™) to a global audience, using the company's innovation platforms to provide people with unprecedented levels of vision, information and situational knowledge about their surroundings in their everyday lives. To accomplish this goal, the firm develops technologies for chemical and biological applications across many global industries; including life sciences, bio-medical, security, threat detection, anatomic pathology, forensics and diagnostics. 

For more information, contact ChemImage.